DK2563400T3 - Modificerede bindeproteiner, der hæmmer VEGF-A-receptorinteraktion - Google Patents

Modificerede bindeproteiner, der hæmmer VEGF-A-receptorinteraktion Download PDF

Info

Publication number
DK2563400T3
DK2563400T3 DK11716429.3T DK11716429T DK2563400T3 DK 2563400 T3 DK2563400 T3 DK 2563400T3 DK 11716429 T DK11716429 T DK 11716429T DK 2563400 T3 DK2563400 T3 DK 2563400T3
Authority
DK
Denmark
Prior art keywords
binding proteins
receptor interaction
inhibit vegf
modified binding
vegf
Prior art date
Application number
DK11716429.3T
Other languages
English (en)
Inventor
Hans Kaspar Binz
Patrik Forrer
Michael Tobias Stumpp
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Application granted granted Critical
Publication of DK2563400T3 publication Critical patent/DK2563400T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DK11716429.3T 2010-04-30 2011-04-29 Modificerede bindeproteiner, der hæmmer VEGF-A-receptorinteraktion DK2563400T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10161685 2010-04-30
PCT/EP2011/056824 WO2011135067A1 (en) 2010-04-30 2011-04-29 Modified binding proteins inhibiting the vegf-a receptor interaction

Publications (1)

Publication Number Publication Date
DK2563400T3 true DK2563400T3 (da) 2019-09-16

Family

ID=42313869

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11716429.3T DK2563400T3 (da) 2010-04-30 2011-04-29 Modificerede bindeproteiner, der hæmmer VEGF-A-receptorinteraktion

Country Status (32)

Country Link
US (5) US8710187B2 (da)
EP (2) EP3593821A1 (da)
JP (1) JP6010528B2 (da)
KR (1) KR101680064B1 (da)
CN (1) CN103002920B (da)
AR (1) AR081361A1 (da)
AU (1) AU2011247563B2 (da)
BR (1) BR112012027368B1 (da)
CA (1) CA2797996C (da)
CL (1) CL2012003025A1 (da)
CO (1) CO6640296A2 (da)
CY (1) CY1122107T1 (da)
DK (1) DK2563400T3 (da)
ES (1) ES2745491T3 (da)
HR (1) HRP20191660T1 (da)
HU (1) HUE045272T2 (da)
IL (1) IL222749B (da)
LT (1) LT2563400T (da)
ME (1) ME03559B (da)
MX (1) MX347535B (da)
MY (1) MY162564A (da)
NZ (1) NZ602943A (da)
PL (1) PL2563400T3 (da)
PT (1) PT2563400T (da)
RS (1) RS59408B1 (da)
RU (1) RU2605309C2 (da)
SG (1) SG185068A1 (da)
SI (1) SI2563400T1 (da)
TW (1) TWI510246B (da)
UA (1) UA111820C2 (da)
WO (1) WO2011135067A1 (da)
ZA (1) ZA201207594B (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643469T3 (es) 2006-04-07 2017-11-23 Aerpio Therapeutics, Inc. Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
JP6173216B2 (ja) 2010-11-26 2017-08-02 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ 設計アンキリンリピートタンパク質のための改善されたキャッピングモジュール
DK2846836T3 (da) 2012-05-07 2019-11-11 Allergan Inc Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi
CN104508129A (zh) 2012-06-28 2015-04-08 分子伴侣公司 设计的与血小板衍生生长因子结合的锚蛋白重复序列蛋白
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
AU2012101677B4 (en) 2012-07-03 2012-12-20 Novartis Ag Device
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2014191574A1 (en) * 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
US20160129080A1 (en) 2013-06-20 2016-05-12 Aaron Osborne Treatment of polypoidal chroidal vasculopathy
US20160137717A1 (en) 2013-06-20 2016-05-19 Gabriela Burian Use of a vegf antagonist in treating choroidal neovascularisation
US20160130321A1 (en) 2013-06-20 2016-05-12 Gabriela Burian Use of a vegf antagonist in treating macular edema
AU2014288847A1 (en) 2013-07-11 2016-01-28 Novartis Ag Use of a VEGF antagonist in treating retinopathy of prematurity
BR112016000177A2 (pt) 2013-07-11 2017-12-12 Novartis Ag usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta
EA201690212A8 (ru) 2013-07-12 2016-08-31 Офтотек Корпорейшн Способы лечения или профилактики офтальмологических патологических состояний
EP3628324A1 (en) * 2013-11-05 2020-04-01 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
WO2015109898A1 (zh) * 2014-01-24 2015-07-30 上海恒瑞医药有限公司 VEGF与PDGFRβ双特异性融合蛋白及其用途
US9388239B2 (en) * 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
KR20170003973A (ko) 2014-05-12 2017-01-10 포르미콘 아게 Ｖｅｇｆ 안타고니스트를 포함하는 사전충전형 플라스틱제 주사기
KR20160075107A (ko) * 2014-12-19 2016-06-29 주식회사 이노테라피 페길화된 vegf 트랩 및 이의 제조방법
NZ735803A (en) 2015-04-02 2021-12-24 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
KR101676690B1 (ko) * 2015-08-04 2016-11-16 (주) 에빅스젠 Vegf 유도-혈관신생 억제효과를 갖는 테트라펩티드 및 이의 용도
MX2018006171A (es) 2015-11-18 2018-12-19 Formycon Ag Jeringa de plastico precargada que contiene un antagonista de vegf.
CN108883057A (zh) 2015-11-18 2018-11-23 Sio2医药产品公司 用于眼科配制品的药物包装
MX2018006092A (es) 2015-11-18 2019-01-31 Formycon Ag Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf.
WO2017129685A1 (en) 2016-01-26 2017-08-03 Formycon Ag Liquid formulation of a vegf antagonist
CN109073660B (zh) 2016-02-29 2022-10-28 麦恩泰科特有限公司 可用于治疗湿性年龄相关性黄斑变性的预测性标志物
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CA3036301C (en) 2016-09-22 2021-04-20 Molecular Partners Ag Recombinant binding proteins comprising ankyrin repeat domains and their use
CN108623694B (zh) * 2017-03-24 2021-09-17 北京市肿瘤防治研究所 血管内皮细胞生长因子受体拮抗肽f56的衍生物及应用
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
EP3630043A1 (en) 2017-05-24 2020-04-08 Formycon AG Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
CA3063995A1 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
EP3856245A4 (en) * 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES TARGETING HPTP-ß (VE-PTP) AND VEGF
CA3139051A1 (en) 2019-06-04 2020-12-10 Christian REICHEN Multispecific proteins
MX2022007120A (es) 2019-12-11 2022-09-09 Molecular Partners Ag Proteínas de unión al complejo péptido-mhc recombinantes y su generación y uso.
KR20230006558A (ko) 2020-05-06 2023-01-10 몰리큘라 파트너스 아게 신규한 안키린 반복 결합 단백질 및 그의 용도
EP4149959A1 (en) 2020-05-14 2023-03-22 Molecular Partners AG Multispecific proteins
AU2021403833A1 (en) 2020-12-16 2023-07-27 Molecular Partners Ag Novel slow-release prodrugs
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用
JP2024509890A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト プロテアーゼ切断可能なプロドラッグ
JP2024509904A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ
WO2022190018A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
JP2024508969A (ja) 2021-03-09 2024-02-28 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
US20240132546A1 (en) 2022-07-31 2024-04-25 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE151110T1 (de) 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
ES2259188T3 (es) 1996-10-25 2006-09-16 Gilead Sciences, Inc. Complejos de ligando de acido nucleico de factor de crecimiento endotelial vascular (vegf).
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
PT1787999E (pt) 1997-04-07 2010-11-11 Genentech Inc Anticorpos anti-vegf
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
CA2289691C (en) 1997-04-23 2008-01-15 Andreas Pluckthun Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
NZ511699A (en) 1998-12-02 2003-02-28 Phylos Inc DNA-protein fusions and uses thereof
JP4670150B2 (ja) * 1999-04-02 2011-04-13 味の素株式会社 多量体蛋白質に由来するサブユニットペプチドの製造法
CN101433715B (zh) 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AU2005250216B2 (en) * 2004-06-01 2009-12-10 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US20060121045A1 (en) * 2004-11-08 2006-06-08 Brent Iverson Antibody fragments for protection from pathogen infection and methods of use thereof
NZ581958A (en) * 2004-11-12 2011-01-28 Bayer Schering Pharma Ag Recombinant newcastle disease virus comprising a transgene encoding a prodrug-converting enzyme or protease for use in the treatment of cancer
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
AU2006268780B2 (en) 2005-07-08 2011-03-24 University Of Zurich Phage display using cotranslational translocation of fusion polypeptides
WO2007103515A2 (en) 2006-03-06 2007-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
CN103183738B (zh) 2006-03-30 2014-08-06 诺瓦提斯公司 c-Met抗体的组合物和使用方法
AU2007267798A1 (en) * 2006-05-26 2007-12-06 Ipsen Pharma S.A.S. Methods for site-specific pegylation
EP2111228B1 (en) 2007-02-02 2011-07-20 Bristol-Myers Squibb Company 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
WO2009040338A1 (en) 2007-09-24 2009-04-02 University Of Zürich Designed armadillo repeat proteins
ES2836948T3 (es) * 2008-11-03 2021-06-28 Molecular Partners Ag Proteínas de unión que inhiben la interacción del receptor de VEGF-A
AR081361A1 (es) * 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
JP6173216B2 (ja) 2010-11-26 2017-08-02 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ 設計アンキリンリピートタンパク質のための改善されたキャッピングモジュール
EP2702069A4 (en) 2011-04-29 2015-04-29 Janssen Biotech Inc IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF
CN104508129A (zh) 2012-06-28 2015-04-08 分子伴侣公司 设计的与血小板衍生生长因子结合的锚蛋白重复序列蛋白
EP2874349B1 (en) 2012-08-01 2018-07-04 Huawei Technologies Co., Ltd. Communication path processing method and apparatus
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2014191574A1 (en) 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor

Also Published As

Publication number Publication date
LT2563400T (lt) 2019-10-10
CN103002920A (zh) 2013-03-27
KR20130076821A (ko) 2013-07-08
US20140221295A1 (en) 2014-08-07
IL222749A0 (en) 2012-12-31
US9289466B2 (en) 2016-03-22
HRP20191660T1 (hr) 2019-12-13
EP3593821A1 (en) 2020-01-15
TW201141509A (en) 2011-12-01
BR112012027368A2 (pt) 2021-06-29
ES2745491T3 (es) 2020-03-02
SI2563400T1 (sl) 2019-11-29
CO6640296A2 (es) 2013-03-22
TWI510246B (zh) 2015-12-01
MX2012012638A (es) 2013-06-28
CN103002920B (zh) 2018-03-02
US8710187B2 (en) 2014-04-29
AR081361A1 (es) 2012-08-29
US9849158B2 (en) 2017-12-26
US10646542B2 (en) 2020-05-12
SG185068A1 (en) 2012-12-28
EP2563400A1 (en) 2013-03-06
RS59408B1 (sr) 2019-11-29
EP2563400B1 (en) 2019-07-10
MX347535B (es) 2017-04-28
US20130116197A1 (en) 2013-05-09
WO2011135067A1 (en) 2011-11-03
UA111820C2 (uk) 2016-06-24
AU2011247563B2 (en) 2014-07-10
BR112012027368B1 (pt) 2024-02-15
RU2012151205A (ru) 2014-06-10
PL2563400T3 (pl) 2020-02-28
RU2605309C2 (ru) 2016-12-20
CY1122107T1 (el) 2020-11-25
ZA201207594B (en) 2013-06-26
ME03559B (me) 2020-07-20
JP6010528B2 (ja) 2016-10-19
NZ602943A (en) 2014-07-25
US20210069293A1 (en) 2021-03-11
CA2797996C (en) 2017-10-03
CL2012003025A1 (es) 2013-08-23
HUE045272T2 (hu) 2019-12-30
US20180125932A1 (en) 2018-05-10
IL222749B (en) 2020-08-31
US20160263185A1 (en) 2016-09-15
MY162564A (en) 2017-06-30
KR101680064B1 (ko) 2016-11-28
PT2563400T (pt) 2019-09-27
AU2011247563A1 (en) 2013-01-10
CA2797996A1 (en) 2011-11-03
JP2013531616A (ja) 2013-08-08

Similar Documents

Publication Publication Date Title
DK2563400T3 (da) Modificerede bindeproteiner, der hæmmer VEGF-A-receptorinteraktion
IL271804A (en) Mice producing binding proteins containing VL domains
LTPA2019012I1 (lt) Plazmos kalikreiną surišantys baltymai
DK2358746T3 (da) Bindingsproteiner til inhibering af vegf-a-receptorinteraktionen
HK1216894A1 (zh) 多價結合蛋白組合物
DK2606061T3 (da) Bindingsproteiner til hepcidin
DK2895503T3 (da) Fibronektinbaserede skeletdomæneproteiner, der binder til myostatin
ZA201306646B (en) Hla-restricted, peptide-specific antigen binding proteins
DK3269802T3 (da) Forbindelser til forbedret virustransduktion
EP2729123A4 (en) CANNABINOID RECEPTOR BINDER AND COMPOSITIONS THEREFOR AND METHOD THEREFOR
DK3409287T3 (da) Antistof-lægemiddelkonjugater (adc), der binder til 191p4d12-proteiner
DK3431492T3 (da) Humane cd30-ligandantigen-bindende proteiner
DK2850103T3 (da) ST2-antigenbindende proteiner
BR112013030352A2 (pt) proteínas de ligação do receptor fc
DK2536830T3 (da) Polypeptider
DK2651436T3 (da) Mycobakterie antigen sammensætning.
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
DK3351255T3 (da) Modificerede anti-cd4-antistoffer
DK2721152T3 (da) Dimere bindingsproteiner baseret på modificerede ubiquitiner
DK3456743T3 (da) Oncostatin m-receptorantigenbindingsproteiner
BR112014009178A2 (pt) métodos, uso, receptor e invenção
EP2855523A4 (en) ANTIGEN BINDING PROTEINS THAT BIND DLL-4
BR112013030897A2 (pt) composição.
DK2639368T3 (da) Gulvindsats til skaktkonstruktioner
DE202010000928U8 (de) Steigbügel